Ipsen board appoints Mariette Finet
Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
This is a routine board-level governance change at a mid-cap pharmaceutical company and is unlikely to move Ipsen's share price or sector sentiment meaningfully. Investors will focus on whether the new director's scientific and investment advisory background influences Ipsen's pipeline strategy in oncology, rare disease and neuroscience.
Ipsen, a French biopharmaceutical company listed on Euronext Paris Paris (IPN) and through a US ADR program (IPSEY), announced on 18 September 2026 the co-optation of Mariette Finet as a Director to its Board of Directors, effective immediately. Finet succeeds Michèle Ollier, who resigned from her director position on 1 August 2026. Finet holds a Doctor of Medicine degree from the University of Nancy and brings more than 35 years of experience in healthcare, pharmaceuticals and life sciences, having begun her career at Laboratoires Beaufour and later holding roles at Beaufour-Ipsen Pharma and Ipsen. Since 2007 she has served in scientific and medical advisory roles at Mayroy and Highrock S.a.r.l., and previously sat on the boards of Lightinderm SAS and Altor BioScience. The board also appointed Finet to its Board Portfolio Committee, replacing Ollier. Her appointment is subject to ratification at the next Annual Shareholders' Meeting, and she will serve the remainder of Ollier's term, which expires at the Annual Shareholders' Meeting approving the financial statements for the year ending 31 December 2026. Following the appointment, Ipsen's board comprises 14 directors, seven women and seven men, including four independent directors and two employee representatives. The change is a routine corporate governance matter with no expected material impact on Ipsen's operations or financial outlook.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard